In this issue:
Low-dose omalizumab for chronic spontaneous urticaria
Guselkumab for moderate-to-severe hidradenitis suppurativa
Tapering dupilumab in atopic dermatitis with low disease activity
Dupilumab-related ocular adverse drug reactions
Upadacitinib in moderate-to-severe atopic dermatitis
Tralokinumab for severe atopic dermatitis
Secukinumab in paediatric patients with plaque psoriasis
Immunisation status during biologic therapy
Post-marketing surveillance of nivolumab + ipilimumab
Risankizumab for plaque psoriasis
Please login below to download this issue (PDF)